earnings
confidence high
sentiment positive
materiality 0.80
Lilly Q1 2022 revenue up 15% to $7.81B; reported EPS $2.10, non-GAAP $2.62; raises guidance
ELI LILLY & Co
2022-Q1 EPS reported
$2.10
revenue$7,810,000,000
- Revenue $7.81B (+15% YoY); volume growth 20%; core product sales up 13 ppt.
- Reported EPS $2.10 (+41%); non-GAAP EPS $2.62 (+63%); both include $0.15 charges.
- 2022 EPS guidance raised: reported $7.30-$7.45; non-GAAP $8.15-$8.30.
- Tirzepatide SURMOUNT-1 obesity Phase 3: up to 22.5% weight loss; 63% of high-dose group lost ≥20% body weight.
- FDA accepted mirikizumab submission for UC; Jardiance EMPA-KIDNEY trial stopped early for positive efficacy.